Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALPG | P10696 | 2/20 | 0.40 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13310544 | 0.83 | FPR2 (0.40) | FPR2ALDH1A1SMN1; SMN2ALPGPLAA | |
| SCHEMBL25424436 | 0.80 | AMPD2 (0.45) | ALDH1A1HTTSMN1; SMN2KMT2A | |
| SCHEMBL22356858 | 0.80 | FPR2 (0.39) | FPR2SMN1; SMN2ALPGPLAAALPL | |
| SCHEMBL2960305 | 0.79 | ALPL (0.50) | ALDH1A1SMN1; SMN2ALPGPLAAALPL | |
| SCHEMBL7896604 | 0.79 | HSP90AA1 (0.45) | FPR2ALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL3587986 | 0.79 | FPR2 (0.49) | FPR2ALDH1A1HTTSMN1; SMN2ALPG | |
| SCHEMBL13010096 | 0.78 | TLR8 (0.45) | FPR2ALDH1A1HTTSMN1; SMN2GAA | |
| SCHEMBL3594313 | 0.75 | GFER (0.56) | ALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL4963238 | 0.75 | SMN1; SMN2 (0.40) | FPR2ALDH1A1HTTSMN1; SMN2GAA | |
| SCHEMBL3581846 | 0.74 | SMN1; SMN2 (0.39) | FPR2ALDH1A1HTTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | FPR2 64/4885ALDH1A1 971/4885HTT 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.